NEW YORK (GenomeWeb) – Transgenomic said today that it has raised $2.2 million through the private placement of preferred stock and warrants with existing investors Crede Capital Group and Third Security.

Separately, the molecular diagnostics firm announced that it has signed an agreement with holders of its outstanding Series A and Series B convertible preferred stock to convert the securities into common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.